. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008 Jul;14(7):767-72. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. The possible role for isoprenoids in modulating certain aging-related phenotypes
    is emphasized by this new work demonstrating that the combination of statins
    and bisphosphonates appears to mitigate these phenotypes, presumably via
    blockade of both farnesylation and geranylgeranylation. Farnesyl transferase
    inhibitors (FTIs) had been reported to have such properties, but
    those observations were apparently less robust in subsequent studies. Another
    aging-related phenomenon, accumulation of amyloid-β peptide in the brains of
    amyloid-depositing transgenic mice, is robustly modulated by statins, yet
    statins have failed in clinical trials to modulate clinical outcome. The new data
    suggest that human Alzheimer trials of statins might be revisited: perhaps
    a clinical trial of statins plus bisphosphonates will reveal efficacy where statins
    alone have failed.

This paper appears in the following:

News

  1. SIRT1, Resveratrol and More: Moving Closer to Anti-aging Elixir?